BRNS

$0.60+$0.02 (+2.99%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$23.8M

41M shares

52-week range

$0.51 – $1.83

7% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

ADRC

Change$-3.50

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$738662	+47.7%	$-1.37	$-1.37–$-1.37	—	1
2027	$0	-100.0%	$-1.46	$-1.46–$-1.46	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.28	$-0.26	+7.1%
2026-04-30	$-0.36	$-0.14	+61.1%
2026-03-13	$-0.40	$-0.27	+32.5%
2025-11-07	$-0.45	$-0.36	+20.0%
2025-08-07	$-0.29	$-0.52	-79.3%
2025-05-07	$-0.34	$-0.49	-44.1%
2025-03-20	$-0.50	$-0.51	-2.0%
2024-11-06	$-0.45	$-0.21	+53.3%

DCF fair valuemodel estimate

Intrinsic value

$1.48

Price

$0.60

Implied upside

+147%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
BRNSBarinthus Biotherapeutics plc	$0.60	+2.99%	$25M	—
ALGSAligos Therapeutics, Inc.	$6.77	-3.29%	$42M	—
CVMCEL-SCI Corporation	$1.49	+0.68%	$10M	—
INMBINmune Bio, Inc.	$2.08	+1.96%	$55M	—
KPTIKaryopharm Therapeutics Inc.	$1.99	-1.97%

Barinthus Biotherapeutics plc American Depositary Shares

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

www.barinthusbio.com

Employees: 14
IPO / List date: Apr 30, 2021
HQ: GERMANTOWN, MD

Held by traders on TradeandTell

No one on the platform currently holds BRNS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	151,000	$85.9K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded BRNS yet.

$BRNS chatter on StockTwits

Tofer@Tofer85Jun 10
$BRNS $PAVS nooobbbbbb!!!!!!
View on StockTwits ↗
johnnygogogo@johnnygogogoJun 9
$BRNS everyone watch and see if the post market weirdness happens again, since you know this is not really a public market
View on StockTwits ↗
Shaybe@Shaybe16569Jun 9
$BRNS any potential catalysts?
View on StockTwits ↗
The Whale@SaudiWhaleBullishJun 9
$BRNS to the moon 😉
View on StockTwits ↗
The Whale@SaudiWhaleJun 9
$PAVS 800% 😍😍 Profits moved to $BRNS @ .70
View on StockTwits ↗
johnnygogogo@johnnygogogoJun 8
$BRNS again
View on StockTwits ↗
johnnygogogo@johnnygogogoJun 5
$BRNS what’s with all the volume after hours? Switching to Clywedog?
View on StockTwits ↗
jorge .miguel@focafoca99May 21
$BRNS secured shareholder approval of its Scheme of Arrangement after a 99.98% vote in favor.
View on StockTwits ↗
SuperGreenToday@SuperGreenTodayMay 19
$BRNS
View on StockTwits ↗
Mike@NVDAMillionaireMay 13
$BRNS Brilliant piece that captures BRNS's situation perfectly. So if you want to update your understanding of BRNS or get to know BRNS better, this is essential reading. https://everyticker.com/quote/BRNS/analysis/barinthus-bio-s-0-67-survival-bet-merger-lifeline-meets-celiac-catalyst-nasdaq-brns
View on StockTwits ↗
Penke Investing@PenkeInvestingMay 4
Fundamental analysis of $BRNS (Barinthus Biotherapeutics plc.) based on financial data and reported results. #BRNS
View on StockTwits ↗
Dan@skyrockets_IncApr 24
@holmyown01 @smooth2222 reverse merger . several companies I've been invested in lately have had 'data due' and the data is late and then it turns out they were working on a reverse merger because they knew data wasn't great. If management knows the data is likely to be bad, they may be looking into these options already as a hedge, becaue if data is bad that's most likely what will happen here. $BRNS $RLYB $CYCN all recent examples of companies that were doing 'business as usual' andthen out of nowhere pivoted even though they had data due.
View on StockTwits ↗
Dan@skyrockets_IncApr 23
@Kinderla $VYNE had a drug toxicity study due then announced RM. $BRNS had VTP-850 that never was released and also VTP-1000 that was due but then annouced RM $RLYB had Phase 1 data that was over a month late , ended up announcing it but then RM annoucement right after. $CYCN was supposed to annoucnce commencement of Phase2 trial in TRD but instead annouced RM. All of these examples at least doubled on the day of the annoucement btw...$CYCN actually did a 6x that day
View on StockTwits ↗
Dan@skyrockets_IncApr 16
$VTGN Any good CEO already has a contingency plan in place in case data is not good. Most likely they are already in talks for some sort of strategic alt deal if the data is meh. $RLYB did it, $CYCN did it, $BRNS did it, $NEUP did it, all behind the scenes while waiting on data and continuing business as usual. With 60m cash on hand Dec 31, and likely 45m+ on hand today we are trading at over 1/2 cash value. Any binary announcement likely has limited downside and loads of upside. Again, no matter the result here I still think it is a asymmetrical risk/reward situation. Risk -30% to possibly gain 100%+ Do your own DD of course but I've loaded up the boat. Options: A). Data is good, stock pumps B). Data is bad, announce strat alt review , stock rebounds to near current levels C). Reverse merger deal out of nowhere, stock explodes based on cash position. Look at $RLYB $CYCN $BRNS etc. All of them happened out of nowhere.
View on StockTwits ↗
Dan@skyrockets_IncApr 13
$PCSA I still maintain this is less about data and more likely a RM play, whether it be a crypto treasury RM w/ Dreyfus or some other company. I think the data continually being delayed is very telling that the company is not planning on continuing on their own. Just my opinion. $BRNS $VYNE and $RLYB all are recent examples of companies who had upcoming data but all ended up doing RM's instead.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.